A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis
|
|
- Camron Jenkins
- 6 years ago
- Views:
Transcription
1 DOI /s ORIGINAL ARTICLE A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis Fernando A. Sommerfleck & Emilce E. Schneeberger & Emilio E. Buschiazzo & José A. Maldonado Cocco & Gustavo Citera Received: 5 May 2012 /Revised: 17 July 2012 /Accepted: 2 August 2012 # Clinical Rheumatology 2012 Abstract This study aimed to develop a simplified version (ASDAS). The study included consecutive patients with ankylosing spondylitis according to modified New York and/or Assessment in Ankylosing Spondylitis 2009 criteria. Sociodemographic data and characteristics of the disease (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Ankylosing Spondylitis Quality of Life (ASQoL)) and erythrocyte sedimentation rate (ESR) were collected. ASDAS simplified version (SASDAS) was calculated as the simple linear sum of the five components of ASDAS which include: patient global assessment using visual analogue scale, back pain (BASDAI question no. 2), peripheral pain and swelling (BASDAI question no. 3), morning stiffness (BASDAI question no. 6), and ESR in millimeters per hour, divided by 10 so as to make it equivalent to the other scale's components. Eighty-six patients were included: 69 (80.2 %) were men with a median age F. A. Sommerfleck : E. E. Schneeberger : E. E. Buschiazzo : J. A. Maldonado Cocco : G. Citera (*) Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Echeverría 955, 1428 Buenos Aires, Argentina gustavocitera@gmail.com F. A. Sommerfleck fersommer@yahoo.com.ar E. E. Schneeberger eschneeb@gmail.com E. E. Buschiazzo emilio.buschiazzo@gmail.com J. A. Maldonado Cocco Maldonado.cocco@fibertel.com.ar of 46 years and median disease duration of 19 years. SAS- DAS showed an excellent correlation with the ASDAS (r0 0.93). SASDAS also showed a good correlation with night pain (r00.60), global pain (r00.69), ASQoL (r00.70), BASFI (r00.75), and BASDAI (r00.96). Using ASDAS cut-off values previously suggested, the corresponding cutoff values for SASDAS were as follows: from 0 to 7.8 (inactive disease), from 7.9 to 13.8 (moderate disease activity), from 13.9 to 27.6 (high disease activity), and above 27.6 (very high disease activity) with optimum sensitivity and specificity. SASDAS showed an excellent correlation with conventional clinical measures of disease activity, and it can be easily calculated and is simple to use in daily clinical practice. Keywords Ankylosing spondylitis. Disease activity. Monitoring disease Introduction Ankylosing spondylitis (AS) is the prototype of the spondyloarthritis and is characterized for affecting mainly young adults between 15 and 30 years old [1 4]. The course of AS is usually progressive with consequent functional deterioration and disability associated with spinal ankylosis and compromise of hip joints which leads to a decrease in the quality of life and a high socioeconomic impact for the patient and the society [5 7]. Therefore, a stringent monitoring of disease activity is essential and, for this purpose, we have several tools, among which the two most frequently used are bath ankylosing spondylitis disease activity index (BASDAI) [8] and, more recently,
2 ankylosing spondylitis disease activity score (ASDAS) [9]. The ASDAS was developed by Assessment in Ankylosing Spondylitis (ASAS) group. It is a composite index made up of three BASDAI questions, patient global assessment using visual analogue scale (VAS), and also an objective laboratory variable such as erythrocyte sedimentation rate (ESR) or C-reactive protein. Though several studies showed that the ASDAS is reliable and reproducible, and in some cases better than BASDAI [10, 11], it is difficult to calculate without using a calculator and therefore arduous to use during daily clinical practice. Currently, there are no simplified indexes to follow-up patient with AS; nevertheless, for measuring disease activity in rheumatoid arthritis patients, Smolen et al. developed the Simplified Disease Activity Index (SDAI) [12]. The SDAI is the sum of five outcome parameters. It is comparable with the DAS28, which easier to calculate and does not require a calculator. Therefore, we decided to develop a simplified version (SASDAS), correlate it with the ASDAS and with conventional clinical measures of disease activity, and establish cut-off points based on the preestablished ASDAS cut-off points [13]. Material and methods The study included consecutive ambulatory patients, older than 16 years old, male and female, and diagnosed with AS according to modified New York [14] and/or ASAS 2009 [15] criteria for axial spondyloarthritis from the Department of Rheumatology of Instituto de Rehabilitación Psicofísica between November 2008 and August Data for each patient were collected on a preselected template. Sociodemographic data (age and gender), disease characteristics, disease duration, and treatments received were recorded. A full physical examination was performed and measures of disease activity such as morning stiffness, night pain, global pain, and BASDAI were performed. Furthermore, Ankylosing Spondylitis Quality of Life (ASQoL) [16] was used to assess the quality of life and the Bath Ankylosing Spondylitis Functional Index (BASFI) [17] was used to assess the functional capacity. The BASFI, BASDAI, and ASQoL questionnaires and the ASDAS index were previously translated and/or validated at our center [7, 18, 19]. Blood samples were taken to determine the ESR by the Westergren method. SASDAS was calculated by the simple linear addition of ASDAS which includes five components: patient global assessment (VAS 0 10 cm), back pain (BAS- DAI question no. 2, 0 10 cm), peripheral pain and swelling (BASDAI question no. 3, 0 10 cm), duration of morning stiffness (BASDAI question no. 6, 0 10 cm), and ESR in millimeters per hour, divided by 10 so as to make it equivalent to the other scale's components. For statistical analysis, descriptive statistics were performed. Correlation between ASDAS and other disease assessment measures was performed by Spearman's test. A multiple linear regression analysis was made using SAS- DAS as dependent variable to assess its main associated variables. Tolerance and variance inflator factor were included in the analysis. Continues variables were compared by ANOVA with Levene's test for homogeneity of variances and pos hoc analysis by Games Howell test. SASDAS cutoff values for different disease stages were analyzed using receiver operating characteristic (ROC) curves. A p value< 0.05 was considered significant. SPSS version 15 statistical package was used for all statistical analysis. Results We included 86 patients: 69 (80.2 %) were men with a median age of 46 years (interquartile range (IQR) 32 58) and a median disease duration of 19 years (IQR 13 31). SASDAS showed an excellent correlation with the ASDAS (r00.93; Fig. 1). SASDAS also showed a good correlation with other classical measures such as global pain and nocturnal pain, BASFI, and BASDAI (Table 1). In multiple linear regression model using SASDAS as dependent variable, variables significantly associated with SASDAS were BASFI and global pain. Age, disease duration, and gender did not show any effect and seem not have any influence on SASDAS values (Table 2). Using the ASDAS cut-off values suggested by ASAS, we divided our group of patients according to those categories. Using ROC curves and those preset cut-off values, we investigated the corresponding cut-off points for the SAS- DAS. Sensitivity and specificity for the new SASDAS cutoffs were determined. The corresponding cut-off values for SASDAS were as follows: inactive disease from 0 to 7.8, moderate disease activity from 7.9 to 13.8, high disease activity from 13.9 to 27.6, and very high activity above Cut-off values showed a high discriminative capacity with 82 % sensitivity and 99 % specificity to differentiate inactive disease from the moderate activity, 90 % sensitivity and 99 % specificity to differentiate moderate activity from high activity, and 93 % sensitivity and 100 % specificity to differentiate high activity from very high activity. When the distribution of BASDAI was analyzed in relation to different SASDAS cut-off points, an upward distribution with a significant difference among the disease stages was observed (Fig. 2).
3 Fig. 1 Correlation between SASDAS and ASDAS 6.00 Spearman Rho: 0.93 ASDAS SIMPLIFIED ASDAS Discussion Main symptoms in AS are pain, stiffness, reduction of spinal mobility, and fatigue. Inflammatory symptoms as well as structural damage generate functional limitations, which affect patients' quality of life. In a study performed at our unit, functional disability correlated positively with disease activity, depression, fatigue, and quality of life and negatively with level of education [7]. Several studies have shown that disease activity correlates with functional capacity and high disease activity is the main cause of functional deterioration in patient with AS. These data show the importance of controlling disease activity in order to ensure an adequate quality of life in the future. BASDAI and ASDAS are the tools to monitor disease activity in patient with AS. Table 1 Correlation of the SASDAS with measures of disease assessment Variables r p BASDAI BASFI Global pain (VAS) Nocturnal pain (VAS) ASQoL BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, VAS Visual Analogue Scale, ASQoL Ankylosing Spondylitis Quality of Life The BASDAI is a self-administered questionnaire and reflects the disease activity. It takes into account the patient vision and is a very useful to measure disease activity in axial spondyloarthritis. The ASAS group developed a composite index, ASDAS, in order to get a more objective measure, including a lab parameter. ASDAS, recently developed, showed that it is a reliable and reproducible, and in accordance with some authors, it would be better than the BASDAI [9 11]. There are two versions: ASDAS-PCR and ASDAS- ESR. Pedersen et al. [10] showed that ASDAS-PCR has higher correlation with the physician and patient global assessment than the BASDAI. In another study, Nas et al. [11] showed that ASDAS-PCR and ASDAS-ESR had Table 2 Multiple linear regression model Variables r standardized coefficient Beta t Significance ASQoL BASFI Global pain (VAS) Age Disease duration Gender Association of SASDAS with different variables of the disease. Dependent variable: SASDAS ASQoL Ankylosing Spondylitis Quality of Life, BASFI Bath Ankylosing Spondylitis Functional Index, VAS Visual Analogue Scale
4 Fig. 2 Distribution of BASDAI as regards different SASDAS cut-off points ANOVA (GAMES-HOWELL) p= better discrimination between high and low activity than BASDAI and acute phase reactants. Others studies found that ASDAS was well correlated with patient's and physician's assessment but was similar to BASDAI [20 22]. We believe that a composite index as ASDAS can reflect and include the different aspects of disease activity. However, the ASDAS presents a composite formula which requires, for its calculation, the use of a scientific calculator or Internet access. For this reason, although we believe in the importance of ASDAS and its excellent correlation with measures of disease activity, given the complexity of its formula, we have retained the five items proposed by ASAS for the formulation of ASDAS but we developed our simplified version. Currently, there are no simplified indexes to follow-up patient with AS. Nevertheless, for measuring disease activity in rheumatoid arthritis patients, several composite indexes which can be simply calculated were developed such as SDAI, Clinical Disease Activity Index, and Indice de Actividad Simplificado [12, 23, 24]. These indexes exhibited an excellent correlation with DAS28 and they have the advantage of not requiring a calculator. This simplified version of the ASDAS is the first simplified composite index for AS and has shown an excellent correlation with ASDAS and other measures of disease activity such as BASDAI and VAS for pain. Regression analysis confirmed the association with disease activity measures and also showed that SASDAS has not been influenced by sex, age, or disease duration. Our study has some limitations. The number of patients included in our study is not large enough so that it will be tested in a larger group of patients and validated in other cohorts. ASAS's recommended formula is ASDAS-PCR and they take ASDAS-ESR as a second option. We decided to simplify the ASDAS-ESR formula in our study. We understand that this would be a minor problem based on thevalidityofbothversions.themainreasonforthis decision was economics; ESR is 10 times cheaper than PCR. Cut-off values for ASDAS were developed by an expert opinion and clinical trials, so we decided to extrapolate these values which showed excellent sensitivity and specificity [12]. However, it would be desirable to test the cut-off values in a larger group of patients including expert opinion and other measures of disease activity. In the same way, sensitivity to change has not been tested in this study and it should be tested in the future. Summing up, the results of our study show that SASDAS is a simple and practical tool to assess disease activity in patient with AS and it can be easily used in clinical practice. Key messages 1. A stringent monitoring of disease activity is essential in patients with ankylosing spondylitis. 2. ASDAS has proved to be a reliable tool to measure disease activity in patients with ankylosing spondylitis. 3. A simplified version of ASDAS is a practical tool to measure disease activity in AS patients and it can be easily to use in clinical practice.
5 Disclosures References None. 1. González-Roces S, Alvarez V (1996) HLA-B27 structure, function, and disease association. Curr Opin Rheumatol 8(4): Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 24: van der Linden S, van der Heijde D (1998) Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am 24: Hammer RE, Maika SD, Richardson JA (1990) Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 63(5): Dalyan M, Guner A, Tuncer S, BilgiÇ A, Arasil T (1999) Disability in ankylosing spondylitis. Disabil Rehabil 21: Masi AT, Walsh EG (2003) Ankylosing spondylitis: integrated clinical and physiological perspectives. Clin Exp Rheumatol 21: Marengo MF, Schneeberger EE, Citera G, Maldonado Cocco JA (2008) Work status among patients with ankylosing spondylitis in Argentina. J Clin Rheumatol 14: Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21: Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patient with ankylosing spondylitis. Ann Rheum Dis 68: Pedersen SJ, Sorensen IJ, Hermann KG et al (2010) Responsiveness (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 69: Nas K, Yildirim K, Cevik R et al (2010) Discrimination ability of ASDAS estimating disease activity status in patient with ankylosing spondylitis. Inter J Rheum Dis 13: Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42: Machado P, Landewé R, Lie E et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70: van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for the modification of the New York criteria. Arthritis Rheum 27: Sieper J, van der Heijde D, Landewé R et al (2009) New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of Spondyloarthritis international Society (ASAS). Ann Rheum Dis 68: Doward L, Spoorerg A, Cook S et al (2003) Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62: Calin A, Garrett SL, Whitelock H, Kennedy LG, O Hea J, Mallorie P et al (1994) A new approach to functional ability in ankylosing spondylitis: the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21: Citera G, Maldonado Cocco J, Moroldo M, Burgos-Vargas R, Anaya J, López I, Gutiérrez M (1999) Validación de la versión en español de los cuestionarios de capacidad funcional (BASFI) y actividad de la enfermedad (BASDAI) en pacientes con Espondilitis Anquilosante en cuatro países latinoamericanos. Rev Argent Reumatol 10(Supl 1):25 [abstract] 19. Buschiazzo E, Sommerfleck F, Schneeberger EE, Arturi P, Maldonado Cocco JA, Citera G (2010) Validación del índice ASDAS en una cohorte de pacientes con Espondilitis Anquilosante. Rev Arg Reumatol 21: Aydin SZ, Can M, Atagunduz P et al (2010) Active disease requiring TNF-alpha antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 28: Eder L, Chandran V, Shen H et al (2010) Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 69: Machado P, van der Heijde D (2011) How to measure disease activity in axial spondyloarthritis? Curr Opin Rheumatol 23: Curet AV, Rillo OL, Chaparro del Moral RE, Papasidero SB, Citera G, Maldonado Cocco JA et al (2005) Modificación y aplicación de un índice de actividad simplificado (IAS) en pacientes con Artritis Reumatoidea. Rev Argent Reumatol Suppl 1: Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:
Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies
Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies 1. Introduction The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new instrument
More information5/4/2018. Outcome Measures in Spondyloarthritis. Learning Objectives. Outcome Measures Clinical Outcome Assessments
Outcome Measures in Spondyloarthritis Marina N Magrey MD Associate Professor Case Western Reserve University School of Medicine at MetroHealth Medical Center Learning Objectives What are outcome measures
More informationTHE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G)
British Journal of Rheumatology 1996;35:66-71 THE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G) S. D. JONES, A. STEINER,* S. L. GARRETT and A. CALIN Royal National Hospital for Rheumatic Diseases,
More informationQuantitative assessment of patients with rheumatic diseases
ORIGINAL ARTICLE Routine Assessment of Patient Index Data (RAPID3) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Yield Similar Information in 85 Korean Patients With Ankylosing
More information2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Online supplementary material
2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis Online supplementary material 1. Introduction A systematic literature review (SLR) was performed to inform the
More informationMethotrexate and leflunomide survival in patients with psoriatic arthritis
International Journal of Clinical Rheumatology Methotrexate and leflunomide survival in patients with psoriatic arthritis Abstract: The objectives of this study were to estimate the survival rate of the
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/43590 holds various files of this Leiden University dissertation Author: Machado, Pedro Title: Health and imaging outcomes in axial spondyloarthritis Issue
More informationAssessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis
140 EXTENDED REPORT Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis A van Tubergen, R Landewé, L Heuft-Dorenbosch,
More informationSerum sclerostin as a possible biomarker in ankylosing spondylitis: a casecontrol
Serum sclerostin as a possible biomarker in ankylosing spondylitis: a casecontrol study Fabio Massimo Perrotta 1, MD, Fulvia Ceccarelli 2, MD, PhD, Cristiana Barbati 2, PhD, Tania Colasanti 2, PhD, Antonia
More informationAnkylosing spondylitis functional and activity indices in clinical practice
Journal of Medicine and Life Vol. 7, Issue 1, JanuaryMarch 2014, pp.7883 Ankylosing spondylitis functional and activity indices in clinical practice Popescu C* **, Trandafir M*, Bădică AM*, Morar F*, Predeţeanu
More informationBRIEF REPORT. Denis Poddubnyy, 1 Hildrun Haibel, 1 J urgen Braun, 2 Martin Rudwaleit, 3 and Joachim Sieper 1
ARTHRITIS & RHEUMATOLOGY Vol. 67, No. 9, September 2015, pp 2369 2375 DOI 10.1002/art.39225 VC 2015, American College of Rheumatology BRIEF REPORT Clinical Course Over Two Years in Patients With Early
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationDo HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation
Do HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging? Results from the DESIR cohort of patients with recent onset axial spondyloarthritis Ho Yin Chung
More informationJane T Osterhaus 1* and Oana Purcaru 2
Osterhaus and Purcaru Arthritis Research & Therapy 2014, 16:R164 RESEARCH ARTICLE Open Access Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing
More informationClinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona
University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationAxial Spondyloarthritis. Doug White, Rheumatologist Waikato Hospital
Axial Spondyloarthritis Doug White, Rheumatologist Waikato Hospital Disclosures Presentations / Consulting Abbott Laboratories AbbVie MSD Novartis Roche Clinical Trials Abbott Laboratories AbbVie Actelion
More informationAssessment of fatigue in the management of patients with ankylosing spondylitis
Rheumatology Advance Access published September 16, 2003 Rheumatology 2003; 1 of 6 doi:10.1093/rheumatology/keg421, available online at www.rheumatology.oupjournals.org Assessment of fatigue in the management
More informationScottish Medicines Consortium
Scottish Medicines Consortium etanercept 25mg vial of powder for subcutaneous injection (Enbrel ) (No. 212/05) Wyeth New indication: severe active ankylosing spondylitis inadequately controlled by conventional
More informationDo extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS
Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS I. Essers 1, S. Ramiro 2, C. Stolwijk 1, M. Blaauw 1, R. Landewé 3, D. van der Heijde 2, F. Van
More informationISPUB.COM. Effects Of Physical And Rehabilitative Treatment On Quality Of Life Of Ankylosing Spondylitis Patients
ISPUB.COM The Internet Journal of Orthopedic Surgery Volume 21 Number 2 Effects Of Physical And Rehabilitative Treatment On Quality Of Life Of Ankylosing Spondylitis Patients B Singh, A Upadhyay, M Garg,
More informationEligibility criteria for TNFi therapy in axspa: BASDAI vs ASDAS
Eligibility criteria for TNFi therapy in axspa: BASDAI vs ASDAS Abstract Background The Ankylosing Spondylitis Disease Activity Score (ASDAS) has been developed as a composite disease activity measure
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 23 April 2009 Doc. Ref. CPMP/EWP/4891/03 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL
More informationI n 1995, the ASsessment in Ankylosing Spondylitis
127 EXTENDED REPORT Assessment of enthesitis in ankylosing spondylitis L Heuft-Dorenbosch, A Spoorenberg, A van Tubergen, R Landewé, H van der Tempel, H Mielants, M Dougados, D van der Heijde... See end
More informationA mong the inflammatory rheumatic diseases
659 REVIEW Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care J Sieper, M Rudwaleit... An earlier diagnosis of ankylosing spondylitis
More informationKey words Ankylosing spondylitis, radiographic scoring methods, intra- and interobserver reliability, BASRI, msasss.
Radiological scoring methods for ankylosing spondylitis: a comparison between the Bath Ankylosing Spondylitis Radiology Index and the modified Stoke Ankylosing Spondylitis Spine Score F. Salaffi 1, M.
More informationClinical Tools to Assess and Monitor Spondyloarthritis
Curr Rheumatol Rep (2015) 17: 47 DOI 10.1007/s11926-015-0522-3 SPONDYLOARTHRITIS (MA KHAN, SECTION EDITOR) Clinical Tools to Assess and Monitor Spondyloarthritis Robert Landewé 1,2 & Astrid van Tubergen
More informationThe Journal of Rheumatology Volume 38, no. 8
The Journal of Rheumatology Volume 38, no. 8 Serum MMP-3 Level as a Biomarker for Monitoring and Predicting Response to Etanercept Treatment in Ankylosing Spondylitis SUZANNE ARENDS, EVELINE van der VEER,
More informationT he spondyloarthritides (SpA) comprise five subtypes:
1305 EXTENDED REPORT Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept M Rudwaleit*, X
More informationKeywords: ankylosing spondylitis, translation, questionnaires, BASFI, health status.
ORIGINAL ARTICLE Cross-cultural adaptation and validation of the Brazilian-Portuguese version of the Bath Ankylosing Spondylitis Functional Index (BASFI) Karla Garcez Cusmanich 1, Sérgio Candido Kowalski
More informationAnkylosing spondylitis: Assessment and analysis of long-term outcome Ramiro, S.
UvA-DARE (Digital Academic Repository) Ankylosing spondylitis: Assessment and analysis of long-term outcome Ramiro, S. Link to publication Citation for published version (APA): Antunes da Cunha Oliveira
More information10/28/2013. Disclosure. Ustekinumab. IL-12, IL-23 and Ustekinumab. IL-23 in Facet Joints in Patients with AS
for the Treatment of Patients with Active Ankylosing Spondylitis: Results of a 28-Week, Prospective, Open-Label, Proof-of-Concept Study (TOPAS) Disclosure The study was supported by an unrestricted research
More informationGuideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis
12 October 2017 EMA/CPMP/EWP/4891/03 Rev.1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Draft agreed by
More informationFactors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex
Law et al. Arthritis Research & Therapy (2018) 20:284 https://doi.org/10.1186/s13075-018-1784-8 RESEARCH Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified
More informationInter-rater reliability of clinical mobility measures in ankylosing spondylitis
Calvo-Gutiérrez et al. BMC Musculoskeletal Disorders (2016) 17:382 DOI 10.1186/s12891-016-1242-1 RESEARCH ARTICLE Open Access Inter-rater reliability of clinical mobility measures in ankylosing spondylitis
More informationJuvenile Idiopathic Arthritis in Adults: Long-Term Observation of Ukrainian Patients
Archive of Clinical Medicine 2017 Vol. 23, Issue 1, E201715 DOI: 10.21802/acm.2017.1.5 Research Article Juvenile Idiopathic Arthritis in Adults: Long-Term Observation of Ukrainian Patients Marta Dzhus
More informationC oping is a cognitive or behavioural effort to manage
1264 EXTENDED REPORT Is avoidant coping independent of disease status and stable over time in patients with ankylosing spondylitis? A Boonen, D van der Heijde, R Landewé, A Chorus, W van Lankveld, H Miedema,
More informationCOSENTYX (secukinumab)
COSENTYX (secukinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationClinical and Imaging Efficacy of Infliximab in HLA B27 Positive Patients With Magnetic Resonance Imaging Determined Early Sacroiliitis
ARTHRITIS & RHEUMATISM Vol. 60, No. 4, April 2009, pp 946 954 DOI 10.1002/art.24408 2009, American College of Rheumatology Clinical and Imaging Efficacy of Infliximab in HLA B27 Positive Patients With
More informationSustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis
Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis E. Martín-Mola 1, J. Sieper 2, M. Leirisalo-Repo 3, B.A.C.
More informationThe effect of infliximab on depressive symptoms in patients with ankylosing spondylitis
ARTIgO ORIgINAL The effect of infliximab on depressive symptoms in patients with ankylosing spondylitis Ersözlü-Bozkırlı ED 1, Ke şkek SO 2, Bozkırlı E 3, Yücel AE 1 ACTA REUMATOL PORT. 2015;40:262-267
More informationLow bone mineral density predicts the formation of new syndesmophytes in patients with axial spondyloarthritis
Kim et al. Arthritis Research & Therapy (2018) 20:231 https://doi.org/10.1186/s13075-018-1731-8 RESEARCH ARTICLE Open Access Low bone mineral density predicts the formation of new syndesmophytes in patients
More informationQuality indicators, guidelines and outcome measures in ankylosing spondylitis
Quality indicators, guidelines and outcome measures in ankylosing spondylitis J. Zochling, J. Braun Jane Zochling, MBBS, MMed (ClinEpi), PhD, Research Fellow, Menzies Research Institute, Hobart, Australia;
More informationDisease and psychological status in ankylosing spondylitis.
Article Disease and psychological status in ankylosing spondylitis. Martindale, J., Smith, J., Sutton, Chris J, Grennan, D., Goodacre, L. and Goodacre, J. A. Available at http://clok.uclan.ac.uk/132/ Martindale,
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationClinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona
University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationPrevalence and clinical significance. of small joint synovitis detected by. ultrasonography in axial SpA
Mémoire de Maîtrise en médecine No 33 Prevalence and clinical significance of small joint synovitis detected by ultrasonography in axial SpA Etudiant Cécile Mouly Tuteur Dr Jean Dudler Clinique de rhumatologie,
More informationTreat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK
Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK Dr Bruce Kirkham Consultant Rheumatologist Guy s & St Thomas NHS Foundation
More informationWhat is Axial Spondyloarthritis?
Physiotherapist Module 2 What is Axial Spondyloarthritis? How does it apply to physiotherapists? Claire Harris, Senior Physiotherapist, London North West Healthcare NHS Trust Susan Gurden, Advanced Physiotherapy
More informationPsychometric validation of the EuroQoL 5-dimension (EQ-5D) questionnaire in patients with spondyloarthritis
Tsang et al. Arthritis Research & Therapy (2019) 21:41 https://doi.org/10.1186/s13075-019-1826-x RESEARCH ARTICLE Psychometric validation of the EuroQoL 5-dimension (EQ-5D) questionnaire in patients with
More informationClinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona
University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationadalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott)
adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott) 08 March 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationHierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data
Arthritis Care & Research Vol. 67, No. 11, November 2015, pp 1571 1577 DOI 10.1002/acr.22614 VC 2015, American College of Rheumatology ORIGINAL ARTICLE Hierarchy of Impairment of Spinal Mobility Measures
More informationThe Relationship Between Clinical Activity And Function In Ankylosing Spondylitis Patients
Bahrain Medical Bulletin, Vol.27, No. 3, September 2005 The Relationship Between Clinical Activity And Function In Ankylosing Spondylitis Patients Jane Kawar, MD* Hisham Al-Sayegh, MD* Objective: To assess
More informationMuhammad Haroon 1* Oliver FitzGerald 4. , Muddassar Ahmad 1, Muhammad Nouman Baig 2, Olivia Mason 3, John Rice 2 and
Haroon et al. Arthritis Research & Therapy (2018) 20:73 https://doi.org/10.1186/s13075-018-1565-4 RESEARCH ARTICLE Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids
More informationPsychological status is associated with drug efficacy in patients with ankylosing spondylitis
International Journal of Clinical Rheumatology Psychological status is associated with drug efficacy in patients with ankylosing Background: Quality of life in patients with Ankylosing Spondylitis (AS)
More informationImpact of Ankylosing Spondylitis on Erectile Function
THE MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL DOI: 10.14744/SEMB.2018.49358 Med Bull Sisli Etfal Hosp Original Research Impact of Ankylosing Spondylitis on Erectile Function İbrahim Halil Erdem, 1 Mazhar
More informationAnkylosing spondylitis (AS) is a chronic inflammatory disorder
DOI 10. 5001/omj.2012.109 Original Article Health-related Quality of Life Assessment on 100 Tunisian Patients with Ankylosing Spondylitis using the SF-36 Survey Wafa Hamdi, Dhouha Azzouz, Mohamed Mehdi
More informationOriginal Article Six-month home-based exercise and supervised training in patients with ankylosing spondylitis
Int J Clin Exp Med 2016;9(3):6635-6641 www.ijcem.com /ISSN:1940-5901/IJCEM0019104 Original Article Six-month home-based exercise and supervised training in patients with ankylosing spondylitis Hengying
More informationMedicine. Observational Study OPEN
Observational Study Medicine Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis
More informationClinical and Experimental Rheumatology 2013; 31:
Scoring with the Berlin MRI method for assessment of spinal inflammatory activity in patients with ankylosing spondylitis: a calibration exercise among rheumatologists L. Carmona 1, A. Sellas 2, C. Rodríguez-Lozano
More informationOptimisation of rheumatology assessments the actual situation in axial spondyloarthritis including ankylosing spondylitis
Optimisation of rheumatology assessments the actual situation in axial spondyloarthritis including ankylosing spondylitis J. Braun, U. Kiltz, X. Baraliakos, D. van der Heijde Rheumazentrum Ruhrgebiet,
More informationShort term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice
Eppeland et al. BMC Research Notes 2013, 6:185 RESEARCH ARTICLE Short term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice Siv
More informationIncreased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis
1473 EXTENDED REPORT Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis V P van Halm, J C van Denderen, M J L Peters, J W R Twisk, M van
More informationAnja Weiß 1*, In-Ho Song 2, Hildrun Haibel 2, Joachim Listing 1 and Joachim Sieper 1,2
Weiß et al. Arthritis Research & Therapy 2014, 16:R35 RESEARCH ARTICLE Open Access Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long
More informationvan der Heijde et al. Arthritis Research & Therapy (2018) 20:61 https://doi.org/ /s
van der Heijde et al. Arthritis Research & Therapy (2018) 20:61 https://doi.org/10.1186/s13075-018-1556-5 RESEARCH ARTICLE Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis
More informationClinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis
More informationSCIENTIFIC DISCUSSION
European Medicines Agency London, 20 September 2007 Product name: Remicade Procedure number: EMEA/H/C/240/II/95 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20)
More informationT he emergence of new treatment options in ankylosing
iii24 EXTENDED REPORT Treatment trials in ankylosing spondylitis: current and future considerations D van der Heijde, J Braun, D McGonagle, J Siegel... See end of article for authors affiliations... Correspondence
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/43590 holds various files of this Leiden University dissertation Author: Machado, Pedro Title: Health and imaging outcomes in axial spondyloarthritis Issue
More informationAssessment of Inflammatory Back Pain: New Concepts in Diagnosis
Assessment of Inflammatory Back Pain: New Concepts in Diagnosis March 2 nd, 2018 Spine Therapy Network Interprofessional Synposium Sheraton Toronto Airport Hotel, Toronto, CANADA Laura Passalent PT, BScPT,
More informationCitation for final published version:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/97756/ This is the author s version of a work that was submitted to / accepted
More informationThe effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Handling editor Tore K Kvien 1 Department of Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany 2 Department of Radiology, Charité Medical School, Berlin, Germany 3 Division of Arthritis & Rheumatic
More informationThe prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis
The prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis G. Bornstein 1,2, M. Lidar 3, P. Langevitz 3, A. Fardman 2, I. Ben-Zvi 4, C. Grossman 4 1
More informationDisease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness
Rheumatology 2002;41:1295 1302 Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness K. L. Haywood 1,2,A.M.Garratt 3,K.Jordan
More information37 year old male with several year history of back pain
37 year old male with several year history of back pain Inflammatory Low Back Pain Clues onset before the age of 40 years insidious onset, chronic (>3 months) pain morning stiffness for longer than 30
More informationRheumatology Subcommittee of PTAC Meeting held 7 October (minutes for web publishing)
Rheumatology Subcommittee of PTAC Meeting held 7 October 2014 (minutes for web publishing) Rheumatology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationPortuguese version of the bath indexes for ankylosing spondylitis patients: a cross-cultural adaptation and validation
DOI 10.1007/s10067-011-1864-5 ORIGINAL ARTICLE Portuguese version of the bath indexes for ankylosing spondylitis patients: a cross-cultural adaptation and validation F. M. Pimentel-Santos & T. Pinto &
More informationResource utilisation and cost of ankylosing spondylitis in Brazil
Resource utilisation and cost of ankylosing spondylitis in Brazil T.M. Torres 1, M.B. Ferraz 1,2, R.M. Ciconelli 1,2 1 Department of Medicine, Division of Rheumatology, and 2 Department of Medicine, São
More informationNonsteroidal Antiinflammatory Drugs Reduce Radiographic Progression in Patients With Ankylosing Spondylitis
ARTHRITIS & RHEUMATISM Vol. 52, No. 6, June 2005, pp 1756 1765 DOI 10.1002/art.21054 2005, American College of Rheumatology Nonsteroidal Antiinflammatory Drugs Reduce Radiographic Progression in Patients
More informationChapter 2 Criteria and Disease Activity Measures in Axial Spondyloarthropathies
Chapter 2 Criteria and Disease Activity Measures in Axial Spondyloarthropathies Jose Aliling 1 and Lawrence H Brent 1* Einstein Medical Center, USA * Corresponding Author: Lawrence H Brent, Einstein Medical
More informationPatient Outcomes in Rheumatoid Arthritis
Patient Outcomes in Rheumatoid Arthritis The impact of rheumatoid arthritis on patients quality of life A small qualitative study involving 25 patients with rheumatoid arthritis in Sweden looked at the
More informationK. Laas 1, R. Peltomaa 1, K. Puolakka 2, H. Kautiainen 3, M. Leirisalo-Repo 1
Early improvement of health-related quality of life during treatment with etanercept and adalimumab in patients with rheumatoid arthritis in routine practice K. Laas 1, R. Peltomaa 1, K. Puolakka 2, H.
More informationAre gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort
Ortolan et al. Arthritis Research & Therapy (2018) 20:218 https://doi.org/10.1186/s13075-018-1705-x RESEARCH ARTICLE Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data
More informationClinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study
EXTENDED REPORT Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study Walter P Maksymowych, 1 Maxime Dougados, 2 Désirée van
More informationNonradiographic axial spondyloarthritis: clinical and therapeutic relevance
Ghosh and Ruderman Arthritis Research & Therapy (2017) 19:286 DOI 10.1186/s13075-017-1493-8 REVIEW Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance Nilasha Ghosh and Eric M.
More informationComparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity
7 Comparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity Charlotte Krieckaert* Anna Jamnitski* Mike Nurmohamed Piet Kostense
More informationI nuovi criteri ACR/EULAR per la classificazione dell artrite reumatoide
I nuovi criteri ACR/EULAR per la classificazione dell artrite reumatoide Pierluigi Macchioni Struttura Complessa di Reumatologia, Ospedale di Reggio Emilia Topics 1987 ACR classification criteria for RA
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationThe Journal of Rheumatology Volume 38, no. 4
The Journal of Rheumatology Volume 38, no. 4 Adalimumab Reduces Pain, Fatigue, and Stiffness in Patients with AS: Results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for AS (ATLAS)
More informationGender differences in effectiveness of treatment in rheumatic diseases
Gender differences in effectiveness of treatment in rheumatic diseases Irene van der Horst-Bruinsma Associate Professor Rheumatology Center of Excellence of Axial Spondyloarthritis ARC/VU University Medical
More informationA nkylosing spondylitis (AS) is a common chronic
1046 EXTENDED REPORT Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems
More informationAnti-TNF-α Therapy for Ankylosing Spondylitis
Original Article Clinics in Orthopedic Surgery 2010;2:28-33 doi:10.4055/cios.2010.2.1.28 Anti-TNF-α Therapy for Ankylosing Spondylitis Jung-Hwan Son, MD, Sang-Won Cha, MD Department of Orthopedic Surgery,
More informationResearch Article Serum Vitamin D and Pyridinoline Cross-Linked Carboxyterminal Telopeptide of Type I Collagen in Patients with Ankylosing Spondylitis
BioMed Research International Volume 2015, Article ID 543806, 6 pages http://dx.doi.org/10.1155/2015/543806 Research Article Serum Vitamin D and Pyridinoline Cross-Linked Carboxyterminal Telopeptide of
More informationSpA non-radiografica: fase precoce di spondilite anchilosante o altro?
Rheumatology Department of Lucania, S. Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera SpA non-radiografica: fase precoce di spondilite anchilosante o altro? Ignazio Olivieri Disclosures
More informationValidity and reliability of the Turkish version of the Health Assessment Questionnaire for the Spondyloarthropathies
Rheumatol Int (2012) 32:1563 1568 DOI 10.1007/s00296-011-1795-0 ORIGINAL ARTICLE Validity and reliability of the Turkish version of the Health Assessment Questionnaire for the Spondyloarthropathies Esra
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs
More informationAdaptation of Chinese and English versions of the Ankylosing Spondylitis quality of life (ASQoL) scale for use in Singapore
Leung et al. BMC Musculoskeletal Disorders (2017) 18:353 DOI 10.1186/s12891-017-1715-x RESEARCH ARTICLE Adaptation of Chinese and English versions of the Ankylosing Spondylitis quality of life (ASQoL)
More information